BACKGROUND: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. PATIENTS AND METHODS: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. RESULTS: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P < .005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P = .001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. CONCLUSION: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.
BACKGROUND: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. PATIENTS AND METHODS: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. RESULTS: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P < .005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P = .001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. CONCLUSION: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.
Authors: Christopher R Flowers; Stacey A Fedewa; Amy Y Chen; Loretta J Nastoupil; Joseph Lipscomb; Otis W Brawley; Elizabeth M Ward Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-06 Impact factor: 4.254
Authors: Erin E Kent; Nancy Breen; Denise R Lewis; Janet S de Moor; Ashley Wilder Smith; Nita L Seibel Journal: Cancer Causes Control Date: 2015-06-18 Impact factor: 2.506
Authors: Yong Liu; Jiehui Deng; Lin Wang; Heehyoung Lee; Brian Armstrong; Anna Scuto; Claudia Kowolik; Lawrence M Weiss; Stephen Forman; Hua Yu Journal: Blood Date: 2012-06-28 Impact factor: 22.113
Authors: Matthew J Matasar; Myron S Czuczman; Maria Alma Rodriguez; Michael Fennessy; Thomas C Shea; Gary Spitzer; Izidore S Lossos; Mohamed A Kharfan-Dabaja; Robin Joyce; Luis Fayad; Kristen Henkel; Qiming Liao; Klaus Edvardsen; Roxanne C Jewell; Doug Fecteau; Rajendra P Singh; Steen Lisby; Craig H Moskowitz Journal: Blood Date: 2013-05-21 Impact factor: 22.113
Authors: Hyeon Gyu Yi; Jin Seok Kim; Cheolwon Suh; Won Seog Kim; Jae-Yong Kwak; Jong-Seok Lee; Yang Soo Kim; Young Don Joo; Yoo Hong Min; Hong Ghi Lee; Sung-Soo Yoon; Jong-Ho Won; Seonyang Park; Hugh Chul Kim; Chul Soo Kim Journal: Blood Res Date: 2013-06-25
Authors: Li Tao; Christina A Clarke; Aaron S Rosenberg; Ranjana H Advani; Brian A Jonas; Christopher R Flowers; Theresa H M Keegan Journal: Br J Haematol Date: 2017-05-25 Impact factor: 8.615
Authors: Min Joung Lee; Se Yeon Park; Jung Hwa Ko; Hyun Ju Lee; Jin Suk Ryu; Jong Woo Park; Sang In Khwarg; Sun-Ok Yoon; Joo Youn Oh Journal: Oncotarget Date: 2017-08-07
Authors: Tanaya Shree; Qian Li; Sally L Glaser; Ann Brunson; Holden T Maecker; Robert W Haile; Ronald Levy; Theresa H M Keegan Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 50.717